Salix swung to a loss in the fourth quarter as the drug maker recorded sharply lower revenue amid a push to clear out inventory ahead of its merger with Valeant.
via WSJ.com: US Business http://ift.tt/18hv2v8
via WSJ.com: US Business http://ift.tt/18hv2v8
Nessun commento:
Posta un commento